Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evolus's Other Operating Expense for the
three
months ended in Mar. 2026 was $1.5 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $5.1 Mil.
Evolus's quarterly Other Operating Expense
increased
from Sep. 2025 ($1.1 Mil) to Dec. 2025 ($1.4 Mil) and
increased
from Dec. 2025 ($1.4 Mil) to Mar. 2026 ($1.5 Mil).
Evolus's annual Other Operating Expense
increased
from Dec. 2023 ($2.2 Mil) to Dec. 2024 ($2.3 Mil) and
increased
from Dec. 2024 ($2.3 Mil) to Dec. 2025 ($4.3 Mil).
Evolus Other Operating Expense Related Terms
Evolus Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Evolus's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of $5.1 Mil mean?
Evolus (EOLS) has a Other Operating Expense of $5.1 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Evolus and its competitors.
Is Evolus' Other Operating Expense too high?
Evolus' current Other Operating Expense is $5.1 Mil. Overall, Evolus has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Other Operating Expense compare to NIKA and EBS?
Evolus' Other Operating Expense of $5.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Evolus and its competitors. Evolus's current Other Operating Expense is $5.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.71, compared to a current price of $5.96 — trading 56.5% below its estimated fair value. The current Other Operating Expense is $5.1 Mil. Evolus' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Evolus (EOLS), the current Other Operating Expense is $5.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $5.96 is trading 56.5% below its estimated GF Value™ of $13.71.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
Other Operating Expense: $5.1 Mil
GF Value™: $13.71 vs. price of $5.96 (56.5% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
68GF Score
Get the complete analysis for EOLS
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
